Caplacizumab for Acquired TTP

Phase III trial with Caplacizumab in patients With acquired Thrombotic Thrombocytopenic Purpura (HERCULES) is now recruiting. For more information visit

Results of phase 2 controlled study to investigate a new drug's ability to reduce treatment time, when administered in addition to the standard-of-care. Read more about this study and other journal articles about TTP in our Resource Links.

NB: Mention of any treatment products associated with this study are provided for information only and their inclusion is not an endorsement of a particular product or company by Answering TTP Foundation.